NBIX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NBIX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-28), Neurocrine Biosciences's current share price is $135.99. Neurocrine Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $9.61. Neurocrine Biosciences's Cyclically Adjusted PB Ratio for today is 14.15.
The historical rank and industry rank for Neurocrine Biosciences's Cyclically Adjusted PB Ratio or its related term are showing as below:
During the past years, Neurocrine Biosciences's highest Cyclically Adjusted PB Ratio was 47.47. The lowest was 1.62. And the median was 15.49.
NBIX's Cyclically Adjusted PB Ratio is ranked worse thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Neurocrine Biosciences's adjusted book value per share data for the three months ended in Dec. 2023 was $22.614. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $9.61 for the trailing ten years ended in Dec. 2023.
The historical data trend for Neurocrine Biosciences's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | 15.67 | 12.48 | 10.95 | 12.32 | 13.72 |
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Neurocrine Biosciences's Cyclically Adjusted PB Ratio for today is calculated as
Cyclically Adjusted PB Ratio | = | Share Price | / | Cyclically Adjusted Book per Share |
= | 135.99 | / | 9.61 | |
= | 14.15 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:
For example, Neurocrine Biosciences's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:
Adj_Book | = | Book Value per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 22.614 | / | 129.4194 | * | 129.4194 | |
= | 22.614 |
Current CPI (Dec. 2023) = 129.4194.
Neurocrine Biosciences Quarterly Data
Book Value per Share | CPI | Adj_Book | |
201403 | 3.257 | 99.695 | 4.228 |
201406 | 3.120 | 100.560 | 4.015 |
201409 | 2.948 | 100.428 | 3.799 |
201412 | 2.729 | 99.070 | 3.565 |
201503 | 5.678 | 99.621 | 7.376 |
201506 | 5.445 | 100.684 | 6.999 |
201509 | 5.204 | 100.392 | 6.709 |
201512 | 4.920 | 99.792 | 6.381 |
201603 | 4.770 | 100.470 | 6.144 |
201606 | 4.392 | 101.688 | 5.590 |
201609 | 4.048 | 101.861 | 5.143 |
201612 | 3.624 | 101.863 | 4.604 |
201703 | 2.824 | 102.862 | 3.553 |
201706 | 3.914 | 103.349 | 4.901 |
201709 | 3.928 | 104.136 | 4.882 |
201712 | 4.191 | 104.011 | 5.215 |
201803 | 4.055 | 105.290 | 4.984 |
201806 | 4.175 | 106.317 | 5.082 |
201809 | 4.935 | 106.507 | 5.997 |
201812 | 5.295 | 105.998 | 6.465 |
201903 | 4.484 | 107.251 | 5.411 |
201906 | 5.284 | 108.070 | 6.328 |
201909 | 6.239 | 108.329 | 7.454 |
201912 | 6.902 | 108.420 | 8.239 |
202003 | 7.546 | 108.902 | 8.968 |
202006 | 8.918 | 108.767 | 10.611 |
202009 | 8.611 | 109.815 | 10.148 |
202012 | 12.045 | 109.897 | 14.185 |
202103 | 12.758 | 111.754 | 14.775 |
202106 | 13.522 | 114.631 | 15.266 |
202109 | 14.198 | 115.734 | 15.877 |
202112 | 14.478 | 117.630 | 15.929 |
202203 | 14.566 | 121.301 | 15.541 |
202206 | 14.889 | 125.017 | 15.413 |
202209 | 16.073 | 125.227 | 16.611 |
202212 | 17.697 | 125.222 | 18.290 |
202303 | 17.277 | 127.348 | 17.558 |
202306 | 18.986 | 128.729 | 19.088 |
202309 | 20.388 | 129.860 | 20.319 |
202312 | 22.614 | 129.419 | 22.614 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thank you for viewing the detailed overview of Neurocrine Biosciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Kevin Charles Gorman | officer: Sr VP, Business Development | 12790 EL CAMINO REAL, SAN DIEGO CA 92130 |
William H Rastetter | director | 9885 TOWNE CENTRE DR., SAN DIEGO CA 92121 |
Kyle Gano | officer: Chief Business Dev Officer | NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
Eiry Roberts | officer: Chief Medical Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130 |
Julie Cooke | officer: Chief Human Resources Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
Gary A Lyons | director, officer: President and CEO | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
Darin Lippoldt | officer: Chief Legal Officer | C/O VOLCANO CORPORATION, 3661 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Jude Onyia | officer: Chief Scientific Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
David W. Boyer | officer: Chief Corp. Affairs Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
Ingrid Delaet | officer: Chief Regulatory Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
Matt Abernethy | officer: Chief Financial Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92121 |
Eric Benevich | officer: Chief Commerical Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12790 EL CAMINO REAL, SAN DIEGO CA 92130 |
Christine A Poon | director | C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933 |
Malcolm Lloyd-smith | officer: Chief Regulatory Officer | 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Stephen A Sherwin | director | C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By PRNewswire • 11-14-2023
By PRNewswire • 01-17-2024
By GuruFocus Research • 10-05-2023
By PRNewswire • 09-21-2023
By PRNewswire • 09-14-2023
By PRNewswire • 01-02-2024
By PRNewswire • 10-10-2023
By GuruFocus Research • 12-25-2023
By GuruFocus Research • 11-30-2023
By GuruFocus Research • 12-16-2023